From: Is CD47 an innate immune checkpoint for tumor evasion?
Therapeutic agent(s) | Details of the therapeutic agent | Clinical trial identifiers | Study start date | Disease in recruited patients |
---|---|---|---|---|
Hu5F9-G4 (NCT02953782 and NCT02953509 use cetuximab and rituximab, respectively, in combination) | • Humanized anti-human CD47 monoclonal antibody • Generated by grafting complementarity determining region (CDR) onto a human IgG4 | 1. NCT02216409 2. NCT02678338 3. NCT02953782 4. NCT02953509 | 1. August 2014 2. November 2015 3. November 2016 4. November 2016 | 1. Solid malignancy 2. Acute myeloid leukemia 3. Solid malignancy and advanced colorectal cancer 4. Relapsed/refractory B cell non-Hodgkin’s lymphoma |
TTI-621 | • A soluble recombinant SIRPα-Fc fusion protein • Generated by combining the sequences encoding the N-terminal portion of human SIRPα with the Fc region of human IgG1 | 1. NCT02890368 2. NCT02663518 | 1. October 2016 2. January 2016 | 1. Solid malignancy and mycosis fungoides 2. Hematologic malignancy |
CC-90002 | • Monoclonal anti-human CD47 antibody | 1. NCT02367196 2. NCT02641002 | 1. March 2015 2. March 2016 | 1. Solid and hematologic malignancies 2. Acute myeloid leukemia and myelodysplastic syndrome |